Literature DB >> 32139613

Encoding, Consolidation, and Renormalization in Depression: Synaptic Homeostasis, Plasticity, and Sleep Integrate Rapid Antidepressant Effects.

Tomi Rantamäki1, Samuel Kohtala2.   

Abstract

Recent studies have strived to find an association between rapid antidepressant effects and a specific subset of pharmacological targets and molecular pathways. Here, we propose a broader hypothesis of encoding, consolidation, and renormalization in depression (ENCORE-D), which suggests that, fundamentally, rapid and sustained antidepressant effects rely on intrinsic homeostatic mechanisms evoked as a response to the acute pharmacological or physiologic effects triggered by the treatment. We review evidence that supports the notion that various treatments with a rapid onset of action, such as ketamine, electroconvulsive therapy, and sleep deprivation, share the ability to acutely excite cortical networks, which increases synaptic potentiation, alters patterns of functional connectivity, and ameliorates depressive symptoms. We proceed to examine how the initial effects are short-lived and, as such, require both consolidation during wake and maintenance throughout sleep to remain sustained. Here, we incorporate elements from the synaptic homeostasis hypothesis and theorize that the fundamental mechanisms of synaptic plasticity and sleep, particularly the homeostatic emergence of slow-wave electroencephalogram activity and the renormalization of synaptic strength, are at the center of sustained antidepressant effects. We conclude by discussing the various implications of the ENCORE-D hypothesis and offer several considerations for future experimental and clinical research. SIGNIFICANCE STATEMENT: Proposed molecular perspectives of rapid antidepressant effects fail to appreciate the temporal distribution of the effects of ketamine on cortical excitation and plasticity as well as the prolonged influence on depressive symptoms. The encoding, consolidation, and renormalization in depression hypothesis proposes that the lasting clinical effects can be best explained by adaptive functional and structural alterations in neural circuitries set in motion in response to the acute pharmacological effects of ketamine (i.e., changes evoked during the engagement of receptor targets such as N-methyl-D-aspartate receptors) or other putative rapid-acting antidepressants. The present hypothesis opens a completely new avenue for conceptualizing and targeting brain mechanisms that are important for antidepressant effects wherein sleep and synaptic homeostasis are at the center stage.
Copyright © 2020 by The Author(s).

Entities:  

Year:  2020        PMID: 32139613     DOI: 10.1124/pr.119.018697

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  6 in total

1.  A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants.

Authors:  Okko Alitalo; Roosa Saarreharju; Ioline D Henter; Carlos A Zarate; Samuel Kohtala; Tomi Rantamäki
Journal:  Prog Neurobiol       Date:  2021-08-14       Impact factor: 10.885

Review 2.  Neurobiological biomarkers of response to ketamine.

Authors:  Bashkim Kadriu; Elizabeth D Ballard; Ioline D Henter; Stephen Murata; Nimesha Gerlus; Carlos A Zarate
Journal:  Adv Pharmacol       Date:  2020-06-18

3.  The Effect of Propofol on a Forced Swim Test in Mice at 24 Hours.

Authors:  David G Daniel; Noah G Daniel; Donald T Daniel; Laura Copeland Flynn; Michael H Allen
Journal:  Curr Ther Res Clin Exp       Date:  2020-06-14

Review 4.  Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.

Authors:  Samuel Kohtala
Journal:  Pharmacol Rep       Date:  2021-02-20       Impact factor: 3.024

5.  The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action.

Authors:  Daniela Dudysová; Karolina Janků; Michal Šmotek; Elizaveta Saifutdinova; Jana Kopřivová; Jitka Bušková; Bryce Anthony Mander; Martin Brunovský; Peter Zach; Jakub Korčák; Veronika Andrashko; Michaela Viktorinová; Filip Tylš; Anna Bravermanová; Tom Froese; Tomáš Páleníček; Jiří Horáček
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

Review 6.  Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.

Authors:  Bashkim Kadriu; Laura Musazzi; Jenessa N Johnston; Lisa E Kalynchuk; Hector J Caruncho; Maurizio Popoli; Carlos A Zarate
Journal:  Drug Discov Today       Date:  2021-08-03       Impact factor: 8.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.